Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive NSCLC
NCT07063329Phase 2Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07063329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063329.